Adoptive transfer of antigen-specific TCR-T cells has demonstrated remarkable clinical outcomes in treating patients with relapsed or refractory AML; particular success has been seen with WT1-specific TCR-T cells (28, 29). This evidence concerns the gene WT1 and acute myeloid leukemia.